Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2016 | Pages:
45 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Vasopressin V1b Receptor (AVPR V1b or AVPR V3 or Antidiuretic Hormone Receptor 1b or Vasopressin V3 Receptor or AVPR3 or AVPR1B) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Vasopressin V1b Receptor (AVPR V1b or AVPR V3 or Antidiuretic Hormone Receptor 1b or Vasopressin V3 Receptor or AVPR3 or AVPR1B) - Pipeline Review, H2 2016', provides in depth analysis on Vasopressin V1b Receptor (AVPR V1b or AVPR V3 or Antidiuretic Hormone Receptor 1b or Vasopressin V3 Receptor or AVPR3 or AVPR1B) targeted pipeline therapeutics. The report provides comprehensive information on the Vasopressin V1b Receptor (AVPR V1b or AVPR V3 or Antidiuretic Hormone Receptor 1b or Vasopressin V3 Receptor or AVPR3 or AVPR1B) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Vasopressin V1b Receptor (AVPR V1b or AVPR V3 or Antidiuretic Hormone Receptor 1b or Vasopressin V3 Receptor or AVPR3 or AVPR1B) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Vasopressin V1b Receptor (AVPR V1b or AVPR V3 or Antidiuretic Hormone Receptor 1b or Vasopressin V3 Receptor or AVPR3 or AVPR1B) - The report reviews Vasopressin V1b Receptor (AVPR V1b or AVPR V3 or Antidiuretic Hormone Receptor 1b or Vasopressin V3 Receptor or AVPR3 or AVPR1B) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Vasopressin V1b Receptor (AVPR V1b or AVPR V3 or Antidiuretic Hormone Receptor 1b or Vasopressin V3 Receptor or AVPR3 or AVPR1B) targeted therapeutics and enlists all their major and minor projects - The report assesses Vasopressin V1b Receptor (AVPR V1b or AVPR V3 or Antidiuretic Hormone Receptor 1b or Vasopressin V3 Receptor or AVPR3 or AVPR1B) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Vasopressin V1b Receptor (AVPR V1b or AVPR V3 or Antidiuretic Hormone Receptor 1b or Vasopressin V3 Receptor or AVPR3 or AVPR1B) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Vasopressin V1b Receptor (AVPR V1b or AVPR V3 or Antidiuretic Hormone Receptor 1b or Vasopressin V3 Receptor or AVPR3 or AVPR1B) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Vasopressin V1b Receptor (AVPR V1b or AVPR V3 or Antidiuretic Hormone Receptor 1b or Vasopressin V3 Receptor or AVPR3 or AVPR1B) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Vasopressin V1b Receptor (AVPR V1b or AVPR V3 or Antidiuretic Hormone Receptor 1b or Vasopressin V3 Receptor or AVPR3 or AVPR1B) Overview 6 Therapeutics Development 7 Vasopressin V1b Receptor (AVPR V1b or AVPR V3 or Antidiuretic Hormone Receptor 1b or Vasopressin V3 Receptor or AVPR3 or AVPR1B) - Products under Development by Stage of Development 7 Vasopressin V1b Receptor (AVPR V1b or AVPR V3 or Antidiuretic Hormone Receptor 1b or Vasopressin V3 Receptor or AVPR3 or AVPR1B) - Products under Development by Therapy Area 8 Vasopressin V1b Receptor (AVPR V1b or AVPR V3 or Antidiuretic Hormone Receptor 1b or Vasopressin V3 Receptor or AVPR3 or AVPR1B) - Products under Development by Indication 9 Vasopressin V1b Receptor (AVPR V1b or AVPR V3 or Antidiuretic Hormone Receptor 1b or Vasopressin V3 Receptor or AVPR3 or AVPR1B) - Pipeline Products Glance 10 Late Stage Products 10 Early Stage Products 11 Vasopressin V1b Receptor (AVPR V1b or AVPR V3 or Antidiuretic Hormone Receptor 1b or Vasopressin V3 Receptor or AVPR3 or AVPR1B) - Products under Development by Companies 12 Vasopressin V1b Receptor (AVPR V1b or AVPR V3 or Antidiuretic Hormone Receptor 1b or Vasopressin V3 Receptor or AVPR3 or AVPR1B) - Therapeutics Assessment 14 Assessment by Monotherapy/Combination Products 14 Assessment by Mechanism of Action 15 Assessment by Route of Administration 17 Assessment by Molecule Type 19 Vasopressin V1b Receptor (AVPR V1b or AVPR V3 or Antidiuretic Hormone Receptor 1b or Vasopressin V3 Receptor or AVPR3 or AVPR1B) - Companies Involved in Therapeutics Development 21 AbbVie Inc. 21 Allergan Plc 22 Azevan Pharmaceuticals, Inc. 23 Laboratorio ELEA S.A.C.I.F. y A. 24 Orphan Therapeutics, LLC 25 Vasopressin V1b Receptor (AVPR V1b or AVPR V3 or Antidiuretic Hormone Receptor 1b or Vasopressin V3 Receptor or AVPR3 or AVPR1B) - Drug Profiles 26 A-988315 - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 ABT-436 - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 AVN-628 - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 desmopressin acetate - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 desmopressin acetate - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 PHT-103 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 Small Molecule to Antagonize Vasopressin V1b Receptor for Depression - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 terlipressin - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 terlipressin - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 Vasopressin V1b Receptor (AVPR V1b or AVPR V3 or Antidiuretic Hormone Receptor 1b or Vasopressin V3 Receptor or AVPR3 or AVPR1B) - Dormant Projects 37 Vasopressin V1b Receptor (AVPR V1b or AVPR V3 or Antidiuretic Hormone Receptor 1b or Vasopressin V3 Receptor or AVPR3 or AVPR1B) - Discontinued Products 38 Vasopressin V1b Receptor (AVPR V1b or AVPR V3 or Antidiuretic Hormone Receptor 1b or Vasopressin V3 Receptor or AVPR3 or AVPR1B) - Featured News & Press Releases 39 May 08, 2016: Studies Demonstrate New Options to Help Prevent and Treat Nocturia 39 May 03, 2016: Allergan Presents New Data on SER120 at the American Urological Association Meeting in San Diego 40 Jan 04, 2013: FDA Grants Orphan-drug Designation For New Terlipressin Formulation For Treatment Of Ascites 40 Apr 23, 2012: Ikaria Obtains Approval For LUCASSIN In Australia 41 Nov 30, 2010: Ikaria Begins Enrollment Of Pivotal Trial For Lucassin 41 Mar 30, 2010: Ikaria Acquires New Drug Application For Lucassin 42 Mar 30, 2010: Ikaria Acquires North American Rights To Lucassin From Orphan Therapeutics 43 Jun 12, 2009: FDA Accepts Final Section Of NDA Filing For Lucassin 43 Appendix 44 Methodology 44 Coverage 44 Secondary Research 44 Primary Research 44 Expert Panel Validation 44 Contact Us 44 Disclaimer 45
List of Tables
Number of Products under Development for, H2 2016 7 Number of Products under Development by Therapy Area, H2 2016 8 Number of Products under Development by Indication, H2 2016 9 Comparative Analysis by Late Stage Development, H2 2016 10 Comparative Analysis by Early Stage Products, H2 2016 11 Number of Products under Development by Companies, H2 2016 12 Products under Development by Companies, H2 2016 13 Assessment by Monotherapy/Combination Products, H2 2016 14 Number of Products by Stage and Mechanism of Action, H2 2016 16 Number of Products by Stage and Route of Administration, H2 2016 18 Number of Products by Stage and Molecule Type, H2 2016 20 Pipeline by AbbVie Inc., H2 2016 21 Pipeline by Allergan Plc, H2 2016 22 Pipeline by Azevan Pharmaceuticals, Inc., H2 2016 23 Pipeline by Laboratorio ELEA S.A.C.I.F. y A., H2 2016 24 Pipeline by Orphan Therapeutics, LLC, H2 2016 25 Dormant Projects, H2 2016 37 Discontinued Products, H2 2016 38
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
